J A M Lehmann1, E Schwarz2, Z Rahmani Azad3, S Gritzka4, T Seifried-Dübon3, M Diebig4, M Gast2, R Kilian5, U Nater6, M Jarczok2, F Kessemeier7, S Braun2, E Balint2, E Rothermund2, F Junne3, P Angerer4, H Gündel2. 1. Department of Psychosomatic Medicine and Psychotherapy, Ulm University Medical Center, Albert-Einstein-Allee 23, 89081, Ulm, Germany. janina.lehmann@uni-ulm.de. 2. Department of Psychosomatic Medicine and Psychotherapy, Ulm University Medical Center, Albert-Einstein-Allee 23, 89081, Ulm, Germany. 3. Department of Psychosomatic Medicine and Psychotherapy, University Hospital Tübingen Osianderstraße 5, 72076, Tübingen, Germany. 4. Institute of Occupational and Social Medicine, Heinrich-Heine-University Düsseldorf, Universitätsstraße 1, 40225, Düsseldorf, Germany. 5. Department of Psychiatry II, Ulm University and Bezirkskrankenhaus Günzburg, Ludwig-Heilmeyer-Str. 2, 89312, Günzburg, Germany. 6. Department for Clinical and Health Psychology, Wien University, Liebiggasse 5, 1010, Wien, Austria. 7. Section of Health Care Research and Rehabilitation Research, Faculty of Medicine, University of Freiburg, Breisacher Str. 153, 79110, Freiburg, Germany.
Abstract
BACKGROUND: Leaders in small and medium-sized enterprises (SMEs) are exposed to increased stress as a result of a range of challenges. Moreover, they rarely have the opportunity to participate in stress management trainings. Therefore, KMU-GO (ger: Kleine und mittlere Unternehmen - Gesundheitsoffensive; en: small and medium-sized enterprises - health campaign) aims at conducting and evaluating such a stress management training. The focus of evaluation does not only lie on the effects on leaders participating but also on their employees. METHODS: The study is planned as a 2 × 3 mixed design with two groups (intervention and waiting control group) as a between factor and point in time (at baseline, 6 and 12 months later) as a within factor. We aim at collecting data from N = 200 leaders. Based on the results of a preceding assessment, an already successfully implemented stress management training was adapted to SME needs and now serves as the framework of this intervention. The stress management training comprises one and a half days and is followed by two booster sessions (each 180 min) about 3 and 6 months after the training. The main focus of this intervention lies on specifying leaders stress reactivity while at the same time investigating its effects on employees' mental health. Further dependent variables are leaders´ depression and anxiety scores, effort-reward imbalance, sick days and psychophysiological measures of heart rate variability, hair cortisol, and salivary alpha-amylase. Cost-effectiveness analyses will be conducted from a societal and employers' point of view. DISCUSSION: Stress management is a highly relevant issue for leaders in SMEs. By providing an adequate occupational stress management training, we expect to improve leaders´ and also employees` mental health, thereby preventing economic losses for SMEs and the national economy. However, collecting data from employees about the success of a stress management training of their leader is a highly sensitive topic. It requires a carefully planned proceeding ensuring for example a high degree of transparency, anonymity, and providing team incentives. TRIAL REGISTRATION: The KMU-GO trial is registered at the German Clinical Trial Register (DRKS): DRKS00023457 (05.11.2020).
RCT Entities:
BACKGROUND: Leaders in small and medium-sized enterprises (SMEs) are exposed to increased stress as a result of a range of challenges. Moreover, they rarely have the opportunity to participate in stress management trainings. Therefore, KMU-GO (ger: Kleine und mittlere Unternehmen - Gesundheitsoffensive; en: small and medium-sized enterprises - health campaign) aims at conducting and evaluating such a stress management training. The focus of evaluation does not only lie on the effects on leaders participating but also on their employees. METHODS: The study is planned as a 2 × 3 mixed design with two groups (intervention and waiting control group) as a between factor and point in time (at baseline, 6 and 12 months later) as a within factor. We aim at collecting data from N = 200 leaders. Based on the results of a preceding assessment, an already successfully implemented stress management training was adapted to SME needs and now serves as the framework of this intervention. The stress management training comprises one and a half days and is followed by two booster sessions (each 180 min) about 3 and 6 months after the training. The main focus of this intervention lies on specifying leaders stress reactivity while at the same time investigating its effects on employees' mental health. Further dependent variables are leaders´ depression and anxiety scores, effort-reward imbalance, sick days and psychophysiological measures of heart rate variability, hair cortisol, and salivary alpha-amylase. Cost-effectiveness analyses will be conducted from a societal and employers' point of view. DISCUSSION: Stress management is a highly relevant issue for leaders in SMEs. By providing an adequate occupational stress management training, we expect to improve leaders´ and also employees` mental health, thereby preventing economic losses for SMEs and the national economy. However, collecting data from employees about the success of a stress management training of their leader is a highly sensitive topic. It requires a carefully planned proceeding ensuring for example a high degree of transparency, anonymity, and providing team incentives. TRIAL REGISTRATION: The KMU-GO trial is registered at the German Clinical Trial Register (DRKS): DRKS00023457 (05.11.2020).
Authors: R Phillips; J Schneider; I Molosankwe; M Leese; P Sarrami Foroushani; P Grime; P McCrone; R Morriss; G Thornicroft Journal: Psychol Med Date: 2014-03 Impact factor: 7.723
Authors: I E H Madsen; S T Nyberg; L L Magnusson Hanson; J E Ferrie; K Ahola; L Alfredsson; G D Batty; J B Bjorner; M Borritz; H Burr; J-F Chastang; R de Graaf; N Dragano; M Hamer; M Jokela; A Knutsson; M Koskenvuo; A Koskinen; C Leineweber; I Niedhammer; M L Nielsen; M Nordin; T Oksanen; J H Pejtersen; J Pentti; I Plaisier; P Salo; A Singh-Manoux; S Suominen; M Ten Have; T Theorell; S Toppinen-Tanner; J Vahtera; A Väänänen; P J M Westerholm; H Westerlund; E I Fransson; K Heikkilä; M Virtanen; R Rugulies; M Kivimäki Journal: Psychol Med Date: 2017-01-26 Impact factor: 7.723
Authors: Nadine Mulfinger; Anja Sander; Felicitas Stuber; Regina Brinster; Florian Junne; Ronald Limprecht; Marc N Jarczok; Tanja Seifried-Dübon; Monika A Rieger; Stephan Zipfel; Martin Peters; Maja Stiawa; Imad Maatouk; Madeleine Helaß; Christoph Nikendei; Eva Rothermund; Nicole Hander; Ute Ziegenhain; Manuela Gulde; Melanie Genrich; Britta Worringer; Janna Küllenberg; Karl Blum; Stefan Süß; Elena Gesang; Sascha Ruhle; Andreas Müller; Jochen Schweitzer-Rothers; Peter Angerer; Harald Gündel Journal: BMC Public Health Date: 2019-12-17 Impact factor: 3.295
Authors: Elisabeth Maria Balint; Peter Angerer; Harald Guendel; Birgitt Marten-Mittag; Marc N Jarczok Journal: Int J Environ Res Public Health Date: 2022-03-24 Impact factor: 3.390